Novel Rapydan(R) Gains Marketing Authorisation In EU For The Relief Of Pain Associated With Needle Puncture And Cannulation

EUSA Pharma announced that Rapydan® (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorisation in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure.

More: continued here

Filed under: Pain / Anesthetics on February 27th, 2008